T. Rowe Price Associates Reports New 5.4% Stake in ORIC Pharmaceuticals

T. Rowe Price Associates, Inc. has filed a Schedule 13G dated May 15, 2026, reporting a new 5.4% ownership stake in ORIC Pharmaceuticals, Inc. (ORIC). As of the event date on March 31, 2026, the investment firm beneficially owns 5,387,783 shares of common stock. According to the filing, T. Rowe Price has sole dispositive power over all 5,387,783 shares and sole voting power over 5,382,293 shares. This represents a significant increase from a previous 0.0% position, crossing the 5% regulatory reporting threshold. The securities were acquired in the ordinary course of business and are not held for the purpose of changing or influencing the control of the issuer. T. Rowe Price Associates, Inc., an investment adviser based in Baltimore, Maryland, explicitly states that this filing should not be construed as an admission of beneficial ownership, which it expressly denies. The filing was signed by Vice President Ellen York.